Skip to main content
Scientists struggle to keep up with demand for CAR-T therapy
6/15/2017

Oncologists and research labs are struggling to keep up with demand for CAR-T therapy as more clinical trials get underway and desperately ill patients seek access to the promising therapy. The treatment, which involves the time-consuming and expensive process of genetically engineering autologous immune cells, is risky but has shown strong results, especially in patients with lymphoma.

Full Story: